Highly Active Antiretroviral Treatment (HAART) for the Prevention of HIV Mother to Child Transmission (PMTCT)
at Roosevelt Hospital’s Infectious Diseases Clinic in Guatemala: The Role of (LPV/r) Standard Dose
264
able measure of adherence, no other adeherence meas-
ures were used, and there was no control arm.
This is an important perspective for a low income
country; it shows that triple combination therapy with a
PI is feasible and better than alternative interventions
such as single dose nevirapine, that can led to higher lev-
els of infections and antiretroviral resistance. The favor-
able maternal and pediatric outcomes and the positive
safety and tolerability of the regimens reported in this
cohort in this setting should be replicated by other
groups.
REFERENCES
[1] World Health Organization, “WHO HIV and Infant
Feeding Technical Consultation Consensus Statement
Held on Behalf of the Inter-Agency Task Team (IATT)
on Prevention of HIV Infections in Pregnant Women,
Mothers and their Infants,” WHO, 2006.
http://www.who.int/hiv/mediacentre/Infantfeedingconsen
susstatement.pf.pdf
[2] A. P. Kourtis, C. H. Schmid, D. J. Jamieson, et al., “Use
of Antiretroviral Therapy in HIV-Infected Pregnant
Women and the Risk of Premature Delivery: A Meta-
Analysis,” AIDS, Vol. 21, No. 13, 2007, pp. 1831-1832.
doi:10.1097/QAD.0b013e3282748e97
[3] P. Brocklehurst and J. Volmink, “Antiretrovirals for Re-
ducing the Risk of Mother-to Child Transmission of HIV
Infection,” C ochrane Data base of Systematic R ev i e ws , Vol.
2, 2007, Article ID: CD003510.
[4] Centro Nacional de Epidemiología, “Estadísticas VIH y
VIH Avanzado Guatemala enero 1984 —Diciembre 2010,”
Guatemala City, 2011.
[5] Estadísticas de Clínica de Enfermedades Infecciosas,
“Hospital Roosevelt. Memoria de Labores, año 2009,”
Guatemala City, 2009. www.infecciosashr.org
[6] World Health Organization, “Antiretroviral Drugs for
Treating Pregnant Women and Preventing HIV Infection
in Infants: Guidelines on Care, Treatment and Support for
Women Living with HIV/AIDS and Their Children in
Resource-Constrained Settings,” World Health Organiza-
tion, Geneva, 2012.
[7] United Nations Joint Programme on HIV/AIDS-UN-
AIDS-2009, “AIDS Epidemic Update NAIDS,” 2009.
http://www.unaids.org/en/media/unaids/contentassets/dat
aimport/pub/report/2009/jc1700_epi_update_2009_en.pdf
[8] C. Mejia, N. Urbizo and V. Gularte, “Lopinavir-Ritonavir
Use in HAART for Pregnant Women in Guatemala, a
Useful and Well Tolerated Option in the PMTC of HIV:
Preliminary Report,” 12th International Congress on In-
fectious Diseases, Lisbon, 15-18 June 2006.
[9] K. M. De Cock, M. G. Fowler, E. Mercier, et al., “Pre-
vention of Mother-to-Child HIV Transmission in Re-
source-Poor Countries: Translating Research into Policy
and Practice,” JAMA, Vol. 283, No. 9, 2000, pp. 1175-
1182. doi:10.1001/jama.283.9.1175
[10] Grupo de Estudio de SIDA, “Recomendaciones de la
SPNS/GESIDA/SEGO/AEP Para el Seguimiento de la
Infección por el VIH con Relación a la Reproducción, el
Embarazo y la Prevención de la Transmisión Vertical,”
Madrid, 2007.
[11] R. E. Tuomala and S. Yawetz, “Protease Inhibitor Use
during Pregnancy: Is There an Obstetrical Risk?” Journal
of Infectious Diseases, Vol. 193, No. 9, 2006, pp. 1191-
1201. doi:10.1086/503049
[12] C. Mejia, J. Romero, D. Rodriguez, et al., “HAART un-
der Restricted Circumstances in the Capital of Guate-
mala, ” The 3rd IAS Conference on HIV Pathogenesis and
Treatment, Rio de Janeiro, 24-27 July 2005.
[13] E. R. Cooper, M. Charurat, L. Mofenson, et al., “Combi-
nation Antiretroviral Strategies for the Treatment of Pre-
gnant HIV-1-Infected Women and Prevention of Perinatal
HIV-1 Transmission,” Journal of Acquired Immune Defi-
ciency Syndromes, Vol. 29, No. 5, 2002, pp. 484-494.
[14] J. S. Read and M. K. Newell, “Efficacy and Safety of
Cesarean Delivery for Prevention of Mother-to-Child
Transmission of HIV-1,” Cochrane Database of System-
atic Reviews, Vol. 4, 2005, Article ID: CD005479.
[15] T. Horvath, B. C. Madi, I. M. Iuppa, et al., “Interventions
for Preventing Late Postnatal Mother-to-Child Transmis-
sion of HIV,” Cochrane Database of Systematic Reviews,
Vol. 1, 2009, Article ID: CD006734.
doi:10.1002/14651858.CD006734.pub2
[16] R. E. Tuomala, D. E. Shapiro, L. M. Mofenson, et al.,
“Antiretroviral Therapy during Pregnancy and the Risk of
an Adverse Outcome,” New England Journal of Medicine,
Vol. 346, No. 24, 2002, pp. 1863-1870.
doi:10.1056/NEJMoa991159
[17] A. P. Kourtis, C. H. Schmid, D. Jamieson, et al ., “Use of
Antiretroviral Therapy in HIV-Infected Pregnant Women
and the Risk of Premature Delivery: A Meta-Analysis,”
AIDS, Vol. 21, No. 5, 2007, pp. 607-615.
doi:10.1097/QAD.0b013e32802ef2f6
[18] C. Perez, A. Galician, E. Luarte and C. Mejia, “Obstetric
Complications and Vertical Transmission in Pregnancy in
Women Who Are HIV Positive, at the Roosevelt Hospital
in 2010,” Gazeta Panamericana de Infectología, Vol. 2,
No. 1, 2012, pp. 43-50.
Copyright © 2012 SciRes. WJA